Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure

Figure 1 Study design and flow algorithm of patient selection. G-CSF: Granulocyte-colony stimulating factor.

Figure 2 Kinetics of peripheral neutrophil count (A) and CD34⁺ cell count (B) in patients treated with granulocyte-colony stimulating factor and controls. ^aP < 0.05, ^bP < 0.01 vs controls. G-CSF: Granulocyte-colony stimulating factor.

Figure 3 Changes in Child-Turcotte-Pugh score (A) and Model for End stage of Liver Disease score (B) in patients treated with granulocyte-colony stimulating factor and control groups. ^aP < 0.05, ^bP < 0.01 vs controls. G-CSF: Granulocyte-colony stimulating factor; CTP: Child-Turcotte-Pugh; MELD; Model for End Stage of Liver Disease.

Figure 4 Survival rate of patients treated with granulocyte-colony stimulating factor and in controls. G-CSF: Granulocyte-colony stimulating factor.